Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
- Sponsor
- Novartis Pharmaceuticals
- Study ID
- NCT01846273
- Phase
- PHASE4
- Status
- Completed
Conditions
- Age-related Macular Degeneration
- Polypoidal Choroidal Vasculopathy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ranibizumab — DRUGIntravitreal injection of 0.5 mg ranibizumab
- Verteporfin PDT — DRUGInfusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
- Sham PDT — DRUGInfusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
Study Details
This study compared the effect of ranibizumab administered as monotherapy versus ranibizumab administered in combination with verteporfin photodynamic therapy (PDT) on visual acuity in patients with symptomatic macular polypoidal choroidal vasculopathy (PCV). The results of this study provided long-term safety and efficacy data used to generate further guidance on the management of patients with PCV.
Key Dates
- Start date
- Aug 7, 2013
- Status verified
- Mar 2019
- Primary completion
- Mar 11, 2016
- Completion
- Mar 2, 2017
Study Design
- Enrollment
- 321 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Ranibizumab + vPDTTreatment initiation with Ranibizumab and verteporfin PDT (vPDT), with re-treatment need (either Ranibizumab alone or combined with vPDT) determined at monthly visits based on defined retreatment criteria
- Active Comparator: Ranibizumab monotherapyTreatment initiation with Ranibizumab and Sham PDT, with re-treatment need (either Ranibizumab alone or combined with Sham PDT) determined at monthly visits based on defined retreatment criteria
Primary Outcome Measure
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 - Study Eye [ Time Frame: Baseline, Month 12 ]
Related Studies
- National Eye Institute Biorepository for Retinal DiseasesRecruiting · National Eye Institute (NEI) · Bethesda, Maryland
- High Resolution Retinal ImagingRecruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- OCT in Rare Chorioretinal DiseasesRecruiting · Oregon Health and Science University · Portland, Oregon
- Stem Cell Ophthalmology Treatment Study IIRecruiting · MD Stem Cells · Westport, Connecticut